NCT07280702

Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 128 (estimated)
• Sponsor: University of Texas Southwestern Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to determine the effectiveness of adding deucravacitinib to the participant's current Psoriatic Arthritis (PsA) treatment to see if it improves their symptoms and quality of life. This study is exploring a new treatment approach that may help improve control of psoriatic disease by targeting different parts of the disease process. By combining therapies that work together, the goal is to offer better symptom relief with fewer or more manageable side effects than some current treatments.

Conditions

• Psoriatic Arthritis (PsA)

Interventions

Type	Name	Description
DRUG	Deucravacitinib	Drug will be administered in tablet form.
DRUG	Placebo	Drug will be administered in tablet form.

Timeline

• Start date: 2026-04-15
• Primary completion: 2027-12-15
• Completion: 2027-12-15
• First posted: 2025-12-12
• Last updated: 2026-04-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study